The National Institute for Health and Care Excellence (NICE) will continue to be faced with more cost-benefit assessments regarding innovative drugs, following the recent rejection of Lecanemab for use on the NHS. In August 2024, the Medicines and Healthcare products Regulatory Agency approved a product licence for Lecanemab for use in slowing disease progression in the early stages of Alzheimer's disease, after a thorough review of the benefits and risks. Subsequently, NICE ruled out offering the drug on the NHS, finding that the benefits were not of sufficient value to the taxpayer to justify the significant cost of making such drugs readily available on the NHS. In this instance, NICE estimated about 70,000 adults in England would have been eligible for treatment with Lecanemab were it approved. The rejection of its use on the NHS means only a small number of patients will likely access the drug in the UK, and will need to do so privately.